Christoph Heuck, M.D.
Clinical and Research Scientist
|
Go to Publications
The Myeloma Institute is at the forefront of research. With a dedicated faculty conducting clinical as well as basic science research, we are at the cutting edge of scientific breakthroughs. Our patients benefit from the rapid transmission of laboratory findings to daily care in the clinical setting.
The Myeloma Institute has received continuous P01 grant funding from the National Cancer Institute for the Project Program "Growth Control of Multiple Myeloma" since 1993 for 20 consecutive years of uninterrupted funding. The objective of the P01 research is to improve growth control of multiple myeloma by dissecting and exploiting the molecular and biological consequences of the multiple myeloma - microenvironment interaction.
The P01's novel translational research has been the core of the UAMS myeloma program. "Translational research" is the term used to describe research that bridges what goes on in the basic science laboratory with developments in clinical care. Breakthroughs in the laboratory are translated into clinical care therapies; outcomes of the therapies in turn provide ideas for further laboratory refinements and pursuits.
Overall goals of the P01 research are to:
- Develop increased understanding of the genetic basis and clinical and biological behavior of myeloma
- Improve diagnostic capabilities
- Further study risk factors and prognostic indicators with goal of individualizing each patient's treatment
- Increase long-term remission and overall survival
Summary of the grant
Curing Multiple Myeloma - The Arkansas Perspective
The issue of curability for multiple myeloma, debated with enthusiasm by some, has been challenged by others preferring to pursue the objective of chronic disease control over disease eradication. Read more
Other currently funded research conducted by Myeloma Institute scientists includes:
Ricky Edmondson, PhD, Associate Professor of Medicine
Multiple Myeloma Research Foundation
"Proteomic Profiling of Multiple Myeloma"
Nancy and Stephen Grand Philanthropic Foundation
"Using Genomics to Better Understand the Biology and Treatment of Multiple Myeloma; high throughput proteomic analysis on isolated myeloma cells from patient bone marrow aspirates"
Ya-wei Qiang, MD, PhD, Assistant Professor of Medicine
Multiple Myeloma Research Foundation
"Defining role of Wnt signaling in multiple myeloma: therapeutic implications"
The goal of this project is to elucidate the role of Wnts in MM pathogenesis including in myeloma biology and bone disease and develop therapeutic approaches to interrupt the molecular targets in Wnt signaling pathways in regulation of myeloma growth and bone disease.
Multiple Myeloma Research Foundation
"Identification of molecular targets in myeloma microenvironment"
The aim of this research is to identify molecular targets that regulate interaction between myeloma cells and their bone marrow microenvironments and provide new insights for designing therapeutic strategies for treatment of myeloma patients.
Frits van Rhee, MD, PhD, Professor of Medicine
National Institutes of Health
"Potentiating natural killer cell anti-myeloma effects"
The aim of this study is to investigate the biology and activity of myeloma patient derived natural killer cells.
Centocor, Inc
“The role of interleukin-6 polymorphism in Castleman’s Disease.”
The aim of this study is to determine whether gene polymorphism plays a role in the etiology of Castleman’s Disease.
Shmuel Yaccoby, PhD, Professor of Medicine
BioInvent International AB
"Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo"
The aims of the study are to: 1) test the effect of a ICAM-1 antibody, BI-505, on myeloma cell growth in coculture with normal bone marrow cells; 2) test the effect of BI-505 on growth of myeloma cells in SCID-hu mice; and, 3) test the effect of BI-505 on NK cell mediated antibody-dependent cellular cytotoxicity against myeloma cells.
View our myeloma abstracts and publications
|